Trichotillomania (TTM) Epidemiology Forecast 2025-2034

Trichotillomania (TTM) refers to a mental health condition where the individual compulsively pulls out or breaks their own hair. It is a relatively uncommon disorder, with research estimates showing that it affects 0.5% to 3.4% of the adult population at some point in their lifetime.

Trichotillomania (TTM) Epidemiology Forecast Report Coverage

The “Trichotillomania (TTM) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of trichotillomania (TTM). It projects the future incidence and prevalence rates of trichotillomania (TTM) across various populations. The study covers age and type as major determinants of the trichotillomania (TTM)-affected population. The report highlights patterns in the prevalence of trichotillomania (TTM) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of trichotillomania (TTM) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Trichotillomania (TTM): Disease Overview

Trichotillomania (TTM) is classified under the overall category of obsessive-compulsive disorder and can seriously impact the well-being and overall quality of life of an individual. Certain genetic mutations and changes in the brain chemistry or structure are suspected to be the possible factors that cause trichotillomania. A person with trichotillomania often has other associated conditions, particularly anxiety and depression, which can occur either separately or due to trichotillomania.

Trichotillomania (TTM): Treatment Overview

Medication, therapy, or a combination of the two are typically involved in the treatment of trichotillomania. Tricyclic antidepressants and selective serotonin reuptake inhibitors can help in reducing the impulse to pull hair. Antipsychotics can also aid in balancing the brain chemistry. Anticonvulsants, that are commonly used to treat seizures and other muscle movement disorders, are reported to help with trichotillomania symptoms.

Epidemiology

The trichotillomania (TTM) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for trichotillomania (TTM) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for trichotillomania (TTM) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that 0.5% to 3.4% of the adult population is affected by trichotillomania.
• According to the first large-scale epidemiological survey of trichotillomania in the general United States population published in Psychiatry Research (2020), 1.7% of individuals aged 18 to 69 reported experiencing trichotillomania.
• Trichotillomania is prevalent in children and adolescents, with the severe form of the condition typically appearing between the ages of 10 and 13.
• In children, trichotillomania occurs equally between boys and girls. However, in adults, the condition tends to affect women much more than men. The ratio in adulthood is estimated to be 9 women for every 1 man with trichotillomania.

Country-wise Trichotillomania (TTM) Epidemiology

The trichotillomania (TTM) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of trichotillomania (TTM) varies significantly between countries due to differences in cultural perceptions, mental health awareness, diagnostic practices, and access to healthcare. In the United States, an estimated 8 million people are affected by trichotillomania, although the overall prevalence is likely to be underestimated.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of trichotillomania (TTM) based on several factors.
• The Trichotillomania (TTM) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of trichotillomania (TTM) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of trichotillomania (TTM) epidemiology in the 8 major markets?
• What will be the total number of patients with trichotillomania (TTM) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of trichotillomania (TTM) in the 8 major markets in the historical period?
• Which country will have the highest number of trichotillomania (TTM) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of trichotillomania (TTM) during the forecast period of 2025-2034?
• What are the currently available treatments for trichotillomania (TTM)?
• What are the disease risks, signs, symptoms, and unmet needs of trichotillomania (TTM)?

This product will be delivered within 3-5 business days.